Nodular sclerosis
Also known as: Nodule, Nodular, Multinodular, Nodulus
Methodology & AI Transparency ⓘ
Nodular sclerosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Nodular sclerosis uses ICD-10 C81.10 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Clinicians assessing Nodular sclerosis focus on microenvironment inflammation [Nodular sclerosis C81.10] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Nodular sclerosis: Pathology / Molecular in Nodular sclerosis (C81.10: Genomic Staging) (Guideline-concordant surveillance (C81.10)) and Complete Blood Count in Nodular sclerosis (C81.10: (ANC, Hemoglobin, Platelets)).
Ask our AI Specialists anything about Nodular sclerosis
What Is Nodular sclerosis?
Recognized across U.S. clinical coding as C81.10 (Cancer & Oncology), Nodular sclerosis (also termed Nodule or Nodular) is evaluated via immunohistochemistry [Nodular sclerosis C81.10] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Nodular sclerosis (ICD-10 C81.10) is driven by microenvironment inflammation [Nodular sclerosis C81.10]; specialists in Cancer, Oncology & Supportive Care monitor Complete Blood Count in Nodular sclerosis (C81.10: (ANC, Hemoglobin, Platelets)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Nodular sclerosis (C81.10): unexplained bleeding, chronic in Nodular sclerosis (C81.10: hoarseness/cough, or progressive)
- • Secondary Nodular sclerosis clinical sign: abnormality detected early in Nodular sclerosis (C81.10: on age-appropriate screening)
- • Symptom flares in Nodular sclerosis correlating with Pathology / Molecular in Nodular sclerosis (C81.10: Genomic Staging) deviation outside Guideline-concordant surveillance (C81.10)
- • Functional cancer & oncology impact requiring immunohistochemistry [Nodular sclerosis C81.10] evaluation (C81.10)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Nodular sclerosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C81.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Nodular sclerosis (C81.10: Genomic Staging) | Guideline-concordant surveillance (C81.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Nodular sclerosis (C81.10: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C81.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Nodular sclerosis (C81.10: Organ Function Panel) | Preserved renal/hepatic clearance (C81.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Nodular sclerosis
Treatment selection for Nodular sclerosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nodular sclerosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Responder analysis using clinically meaningful thresholds: Post hoc analyses from: What a 311-Participant Study Found Significantly greater proportion of dupilumab-treated patients with PN, versus placebo, demonstrated clinically meaningful improvements in PRO measures of symptoms and QoL. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-10-15 • Phase III Randomized Trial | N = 311 | 93/100 | PMID 38785405 ↗ |
| New Insights on Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized: What a 1,284-Participant Study Found MUSIC-Screen will determine whether microUS can be used as an imaging modality to inform biopsy decision making that is non-inferior to mpMRI for GG ≥ 2 prostate cancer detection. Contemporary clinical trials • 2026-09-15 • Phase III Randomized Trial | N = 1,284 | 90/100 | PMID 42476253 ↗ |
| Can This Approach Help? Inside the Latest Research on Health-related quality of life and pain with selinexor in patients with advanced Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Future oncology (London, England) • 2021-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33855868 ↗ |
| What the Latest Evidence Really Says About Menopausal hormone therapy after breast cancer: the Stockholm randomized Statistically significant heterogeneity in the rate of recurrence was observed (P = .02; two-sided likelihood-ratio test) between the two studies, indicating that chance may not be the only explanation. Journal of the National Cancer Institute • 2005-04-06 • Meta-Analysis | Multi-cohort | 86/100 | PMID 15812079 ↗ |
| Can This Approach Help? Inside the Latest Research on Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: Tumour resections for TIL-IMP manufacture lead to limited surgical complications. The British journal of surgery • 2025-05-31 • Phase III Randomized Trial | N = 80 | 82/100 | PMID 40474841 ↗ |
Nodular sclerosis Patient Community & “People Like Me” Threads
Filter Nodular sclerosis community threads and patient logs by age, biological sex, dosage, and treatment duration.